Abstract
BackgroundRA pts treated with TCZ showed superior clinical benefit vs pts treated with ADA in the ADACTA study1; however, it is unclear whether distinct RA subpopulations responded preferentially to anti-IL6R...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
